Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EN-RX3
- Development stage
- Preclinical
- Lead developer
- Enedra Therapeutics
01
Overview
EN-RX3 is a preclinical-stage precision medicine program being developed by Enedra Therapeutics for the treatment of solid tumours. The program is built upon Enedra's proprietary CASPAROV™ platform, which utilizes computational analysis of cancer evolution and chromosomal instability to identify novel drug targets. EN-RX3 specifically targets tumours stratified by Convergent Genomic Signatures (CGS), a proprietary biomarker technology designed to identify patients most likely to benefit from the therapy. As of early 2024, the program is at the candidate stage, though the specific molecular target, drug modality, and route of administration remain undisclosed by the developer.
Beyond the preview
Go deeper on EN-RX3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EN-RX3.